STOCK TITAN

Embecta Corp. - EMBC STOCK NEWS

Welcome to our dedicated page for Embecta news (Ticker: EMBC), a resource for investors and traders seeking the latest updates and insights on Embecta stock.

Embecta Corp. (Nasdaq: EMBC) is a leading medical technology company, dedicated to developing innovative technologies, services, and solutions that advance clinical therapies for patients and enhance clinical processes for healthcare providers. The company’s core products include the BD Pyxis, PureWick, and Phasix, which have significantly impacted healthcare delivery and patient outcomes.

Embecta has recently celebrated an important milestone, marking 100 years since the development of the first syringe dedicated to insulin delivery. This heritage underscores its deep-rooted commitment to improving the lives of people with diabetes. Embecta’s global impact is further enhanced through partnerships with leading advocacy and professional groups, striving to raise awareness and provide better solutions for diabetes care.

Financially, Embecta has shown robust performance, consistently demonstrating strong revenue growth. The company's Board of Directors recently declared a quarterly cash dividend of $0.15 per share, payable on September 13, 2023. Embecta regularly evaluates its financial results on both a reported and Constant Currency basis to provide a clear picture of its operational performance, excluding the effects of currency fluctuations.

Embecta continues to spearhead significant projects and initiatives. For instance, its recent symposium at the Advanced Technologies & Treatments for Diabetes (ATTD) international conference showcased the company’s commitment to innovative insulin pump therapies for type 2 diabetes. Furthermore, Embecta has been proactive in responding to regulatory requirements like the EU MDR and GDPR, ensuring compliance while continuously improving its products and services.

With approximately 2,000 dedicated employees worldwide, Embecta leverages its rich legacy and innovative spirit to empower people with diabetes to live their best lives. Through strategic partnerships and a relentless focus on quality and reliability, Embecta remains at the forefront of diabetes care.

Rhea-AI Summary

Embecta Corp. (Nasdaq: EMBC), a global diabetes care company specializing in insulin delivery, has announced its upcoming fiscal third quarter 2024 financial results conference call. The event is scheduled for Friday, August 9, 2024, at 8:00 a.m. Eastern Time. During the call, the company will discuss financial results, provide an operational update, and host a Q&A session. Interested parties can access the live webcast through the provided link or via the company's investor relations website. A teleconference option is also available. For those unable to attend live, a webcast replay will be accessible from 11:00 a.m. ET on the same day and will remain archived on the website for one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
conferences earnings
-
Rhea-AI Summary

Embecta presented two abstracts at the ADA's 84th Scientific Sessions, highlighting the potential benefits of a 300-unit insulin reservoir patch pump for adults with type 2 diabetes (T2D). Research indicated that the larger reservoir could reduce the need for frequent patch changes and better accommodate daily insulin needs. One study found that insulin total daily dose (TDD) was influenced by factors such as BMI and medication type. Another analysis showed that a 300u reservoir would meet the needs of 64% of T2D patients for 72-hour wear compared to 38% for a 200u reservoir. Embecta has submitted a 300u insulin delivery system to the FDA for approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
-
Rhea-AI Summary

Zimmer Biomet has announced the appointment of Devdatt Kurdikar to its Board of Directors, effective immediately. Kurdikar is currently the President, CEO, and a board member of Embecta, a leading diabetes management company. His extensive experience in the medical technology sector includes leadership roles at BD, Cardiac Science, Boston Scientific, and Baxter International. Zimmer Biomet's Chairman, Chris Begley, emphasized the value Kurdikar's expertise will bring as the company advances its strategic priorities. Kurdikar holds advanced degrees in Chemical Engineering and an MBA, and has a strong background in medtech innovation and leadership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary

Embecta Corp. reported solid financial results for Q2 and the first half of fiscal year 2024, showcasing resilience in base business and strong operational execution. The company saw revenue growth, increased gross profit and margin, and positive adjusted net income. Strategic highlights include strengthening the base business and investing for growth with FDA review progress on insulin delivery systems.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
37.88%
Tags
-
Rhea-AI Summary

Embecta Corp. (EMBC) announced a quarterly cash dividend of $0.15 per share for stockholders, payable on June 14, 2024. The dividend will be given to shareholders of record as of May 28, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
37.88%
Tags
dividends
-
Rhea-AI Summary

Embecta Corp. (

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
conferences
Rhea-AI Summary
Embecta Corp. to host a conference call to discuss fiscal second quarter 2024 financial results, providing an operational update and Q&A session on May 9, 2024. The live webcast and teleconference will be available for participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
conferences earnings
-
Rhea-AI Summary
Revelyst appoints Joe Beck as Chief Supply Chain Officer to lead business transformation and efficiency efforts. Beck brings extensive experience in global supply chain operations and logistics, with a proven track record of success. His strategic vision aligns with Revelyst's goal of becoming the industry's top brands house, driving growth and innovation. Beck's appointment signals a pivotal moment for Revelyst as it restructures its business model and invests in high-potential brands for accelerated growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
-
Rhea-AI Summary
Embecta Corp. sponsors a symposium at the ATTD conference focusing on insulin pump therapy for T2D care, showcasing six scientific posters. The event aims to enhance informed decision-making for patients with type 2 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Embecta Corp. (EMBC) reports strong financial results for the first quarter of fiscal year 2024, with revenues of $277.3 million and various key financial metrics exceeding expectations. The company made progress on strategic priorities, including the 510(k) filing of an open-loop patch pump with the FDA. Despite a slight decrease in U.S. revenues, international revenues saw an increase. The company raised its guidance for certain financial metrics for the year. Embecta also announced a dividend of $0.15 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.47%
Tags

FAQ

What does Embecta Corp. specialize in?

Embecta Corp. is a medical technology company focused on developing innovative technologies, services, and solutions that advance clinical therapies for patients and enhance clinical processes for healthcare providers.

What are some of Embecta's key products?

Some of Embecta's key products include BD Pyxis, PureWick, and Phasix, which have significantly impacted healthcare delivery and patient outcomes.

How long has Embecta been involved in diabetes care?

Embecta has been involved in diabetes care for nearly 100 years, celebrating its legacy in insulin delivery solutions.

What recent financial milestone has Embecta achieved?

Embecta's Board of Directors declared a quarterly cash dividend of $0.15 per share, payable on September 13, 2023.

How does Embecta report its financial results?

Embecta reports its financial results on both a reported and Constant Currency basis to provide a clear picture of its operational performance, excluding the effects of currency fluctuations.

What strategic initiatives is Embecta currently focusing on?

Embecta focuses on innovative projects like insulin pump therapies for type 2 diabetes and compliance with regulatory requirements such as the EU MDR and GDPR.

How does Embecta contribute to diabetes awareness?

Embecta collaborates with leading advocacy and professional groups to raise awareness and provide better solutions for diabetes care.

Where are Embecta's main manufacturing operations located?

Embecta's main manufacturing operations for plastic insulin syringes are located in Holdrege, Nebraska.

How does Embecta support its workforce?

Embecta leverages the passion and expertise of its approximately 2,000 employees worldwide, supporting them through strategic initiatives and a focus on quality and reliability.

What is the significance of Embecta's recent symposium at ATTD?

The symposium highlighted the significance of insulin pump therapy for type 2 diabetes, showcasing Embecta's commitment to innovative diabetes care solutions.

Embecta Corp.

Nasdaq:EMBC

EMBC Rankings

EMBC Stock Data

875.43M
57.67M
0.47%
99%
5.77%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
WILMINGTON